Latest News and Press Releases
Want to stay updated on the latest news?
-
Active Biotech erhåller delmålsbetalning om 10 miljoner euro Lund (Sverige) och Paris (Frankrike), den 10 december, 2012. Active Biotech (NASDAQ OMX NORDIC: ACTI) och Ipsen (Euronext: IPN; ADR:...
-
· Full recruitment triggers a €10 million milestone payment to Active Biotech Lund (Sweden) and Paris (France), December 10, 2012, Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext:...
-
Five Novel Therapeutic Candidates Progressing Through Clinical Development, Including One Phase 3 Trial in Second Line Pancreatic Cancer and Four Phase 2 Trials in Multiple Cancer...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Continued, steady improvements in the manufacturing...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Stadige forbedringer i produktionen af IMVAMUNE®...
-
· Laquinimod - Teva inleder ny fas III-studie vid årsskiftet - delmålsbetalning om 5 MUSD erhållen efter inlämnad registreringsansökan i Europa - Fas II-data...
-
· Laquinimod - Teva to initiate a new Phase III study in the US at year-end - milestone payment of USD 5 M received following a submitted application for regulatory approval in...
-
· Laquinimod - Teva inleder ny fas III-studie vid årsskiftet - delmålsbetalning om 5 MUSD erhållen efter inlämnad registreringsansökan i Europa - Fas II-data...
-
ORION OYJ OSAVUOSIKATSAUS 1-9/2012 23.10.2012 klo 12:00 Orionin liikevaihto tammi-syyskuulta 2012 oli 726 miljoonaa euroa (682 miljoonaa euroa vuoden 2011 tammi-syyskuussa),...
-
ORION CORPORATION / INTERIM REPORT / JANUARY-SEPTEMBER 2012 / 23 October 2012 at 12:00 noon EEST Orion's net sales for January-September 2012 totalled EUR 726 million (EUR 682 million for...